Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted)

Arexvy is a vaccine that helps protect adults from RSV, a virus that can cause serious lung infections. It is a single shot given into the arm muscle. It teaches the immune system to recognize and fight the virus.

Brand names:Arexvy
Medication

What people taking Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted)

What It's For

Arexvy is a vaccine made by GSK that protects adults against respiratory syncytial virus, or RSV. In most healthy adults RSV causes a cold. In older adults and people with chronic heart or lung disease, diabetes, kidney or liver disease, or a weakened immune system, it can spread into the lungs and cause pneumonia, worsen heart failure or COPD (chronic obstructive pulmonary disease), and lead to a hospital stay. Arexvy is meant to prevent that lower respiratory tract disease, meaning infection of the airways and lungs rather than the nose and throat. The FDA has approved it for everyone 60 and older and for adults 18 to 59 who are at increased risk of serious RSV illness. The CDC's recommendation is narrower than the approval: one dose of RSV vaccine for all adults 75 and older, and for adults 50 to 74 who have a condition or circumstance that raises their risk, such as chronic lung or heart disease, moderate or severe immune compromise, diabetes, or living in a nursing home. Two other RSV vaccines are available for adults in the US, Abrysvo (Pfizer) and mResvia (Moderna), and the CDC recommendation applies to any of the three.

How It Works

RSV uses a surface protein called the F (fusion) protein to merge with and enter the cells lining the airways. Before it does this, the protein holds a particular shape, called the pre-fusion form, and antibodies that recognize that shape are especially good at blocking infection. Arexvy contains a lab-made copy of the F protein locked in its pre-fusion shape. It contains no virus and cannot cause RSV. It also contains an adjuvant called AS01E, an ingredient that strengthens the immune system's response to the protein. This matters because the immune system becomes less responsive with age. After vaccination, the body makes antibodies and immune cells primed to recognize RSV, so if the virus is encountered later, the infection is less likely to reach the lungs or become severe.

Dosage & Administration

Arexvy is given as a single injection into the upper arm muscle. The clinic or pharmacy mixes a powder with a liquid adjuvant just before giving it, so there is nothing to prepare or take at home. It is a one-time vaccine, not a yearly shot like the flu vaccine. Current CDC guidance is that people who have already had any RSV vaccine should not get another dose, because whether and when a booster helps is still being studied. Ideally it is given before RSV season begins, since the virus in the US usually circulates from fall into spring, but it can still be given later to someone who is eligible and unvaccinated. If you are moderately or severely ill on the day of your appointment, with or without fever, vaccination is usually postponed until you recover. A mild cold is generally not a reason to wait.

Side Effects

Most reactions are short-lived and show the immune system responding. In studies of people 60 and older, about 6 in 10 had a sore arm, and about a third felt tired; muscle aches, headache and joint pain were also common. These typically last a day or two. Younger adults reported them more often: among people 18 to 49 in a study, about three quarters had arm pain and more than half had muscle aches or fatigue. Some people faint shortly after any injection, which is why clinics may ask you to sit for a few minutes afterward. Guillain-Barré syndrome (GBS) is a rare condition in which the immune system attacks the nerves, causing weakness that can spread and, in severe cases, affect breathing. A study of Medicare data in people 65 and older found a higher risk of GBS in the 42 days after Arexvy, estimated at about 7 extra cases per million doses. The FDA says this suggests a risk but does not prove the vaccine caused it. If you develop tingling or weakness that starts in the legs and spreads, or trouble walking, in the weeks after vaccination, contact your doctor right away. Severe allergic reactions are rare. Trouble breathing, swelling of the face or throat, or hives with dizziness soon after vaccination need emergency care: call 911.

Interactions & Warnings

Do not get Arexvy if you have had a severe allergic reaction, such as anaphylaxis, to any of its ingredients. If you have had a serious reaction to another vaccine, mention it before your appointment. Arexvy is not for use during pregnancy. In a study of pregnant people given a related experimental RSV vaccine without the adjuvant, more babies were born early than in the placebo group. Abrysvo is the RSV vaccine used during pregnancy to protect newborns, and that is a separate decision to discuss with an obstetric team. People with a weakened immune system, including those taking medicines that suppress immunity after an organ transplant, may make fewer protective antibodies, and studies have not shown how well the vaccine prevents illness in this group. Vaccination is still often recommended for them, but other precautions against respiratory infections continue to matter. Arexvy can be given at the same visit as other adult vaccines, including flu shots. Antibody levels were somewhat lower in studies when it was given with a flu vaccine, though it is not known whether this affects protection, and getting several shots at once may make arm soreness and tiredness more noticeable. Arexvy's adjuvant belongs to the same family as the one in Shingrix, GSK's shingles vaccine, and there is little information yet on giving the two at the same visit, so it is reasonable to ask about spacing them.

What to Expect

Protection starts in the weeks after the shot. In the main trial of about 25,000 adults 60 and older, one dose prevented about 83% of RSV lung infections during the first RSV season and about 94% of severe cases. Protection declines over time: averaged over three seasons it was about 63%, and in the third season alone it was about 48%. That waning is why researchers are still studying whether a later dose will be needed. The trial did not include enough people over 80 to measure benefit precisely in that group, and it excluded people with weakened immune systems. In practice, most people have a sore arm and possibly a day of feeling tired or achy, then nothing further. RSV still circulates every year, and the vaccine lowers rather than eliminates the risk, so it is still worth seeking care if you develop worsening breathing problems during a respiratory illness, especially if you have heart or lung disease. Keep a record of the date and product, since you are not expected to need it again.

Questions to Ask Your Doctor

  1. 1.Do my age and health conditions put me in a group that is recommended to get an RSV vaccine?
  2. 2.Is there a reason to choose Arexvy over Abrysvo or mResvia for me?
  3. 3.Should I get it at the same visit as my flu, COVID-19 or shingles vaccine, or space them out?
  4. 4.Given my immune system or medications, how well is the vaccine likely to work for me?
  5. 5.I have had Guillain-Barré syndrome or a serious vaccine reaction before. Does that change whether I should get this vaccine?

Last reviewed • Oct 2026

Educational content, not medical advice.